Login
Navigate Fool.com
Will NWBO beat
the market?

Northwest Biotherapeutics (NASDAQ: NWBO)

Community Rating: 1 Star: Ominous

6.41 0.13 (2.07%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.23
Previous Close $6.28
Daily Range $6.19 - $6.45
52-Week Range $3.10 - $10.64
Market Cap $366.6M
P/E Ratio -2.68
Dividend (Yield) $0.00 (0.0%)
Volume 384,034
Average Daily Volume 1,569,457
Current FY EPS -$1.70

How do you think NWBO
will perform against the market?

Top NWBO Bull/Bear Pitches

 

martynanasi (< 20)
Submitted March 11, 2014

Recently approved drug DCVax-L apporved in Germany ahead of phase III trail completion. WIll be allowed to prescribed for 5yr and can be extended. Previous trials point to sustain life span of existin … More

0 Replies Reply Report this Post
 

zzlangerhans (< 20)
Submitted December 27, 2013

Long-term Northwest shareholders make me think of a particularly dumb herd of wildebeest on the Serengeti. A couple of weeks ago a pride of lions pounced on the Immunocellular wildebeests and tore the … More

11 Replies Reply Report this Post

News & Commentary Rss Feed

3 Health Care Trends That Could Smoke Marijuana's Growth Potential

If you think marijuana offers the best growth potential in the health-care sector, then you haven't been paying attention to these three rapidly-growing trends.

This Week in Biotech: Tulipmania Ensues in the Hepatitis C Sector

Five clinical updates that made waves in the biotech sector this week, as well as the surprising buyout that still has Wall Street abuzz.

Why Synaptics, Ulta Salon, and Northwest Biotherapeutics Are Today's 3 Best Stocks

The S&P 500 suffers its worst loss in weeks even as Synaptics, Ulta Salon, and Northwest Biotherapeutics shares all soar by double digits.

Why Northwest Biotherapeutics Inc. Shares Hit a High Note

Northwest Biotherapeutics shares soar following what might be described as "perfect" data in its phase 1/2 DCVax-Direct study on inoperable solid tumors.

Sector Update: Healthcare Stocks Mixed in Afternoon Trade; Northwest Biotherapeutics Rallies on DCVa

Sector Update: Healthcare Stocks Mixed in Afternoon Trade; Northwest Biotherapeutics Rallies on DCVax Trial Results

Sector Update: Healthcare

This Week in Biotech: VIVUS Attracts Buyout Interest While BioCryst Wows Investors

One mega-merger falls through the cracks, another struggling biotech draws buyout interest, and three biotechs deliver impressive clinical results.

Why Northwest Biotheraputics, Inc. Shares Were Flying High Today

Is this meaningful? Or just another movement?

This Week in Biotech: Celldex Buddies Up While Isis' Experimental Diabetes Therapy Impresses

Celldex finds a partner, Isis dazzles Wall Street with type 2 diabetes data, and Novartis lays an egg. These are just some of this week's top biotech stories.

Why Northwest Biotherapeutics Inc. Shares Briefly Soared

Northwest Biotherapeutics excited shareholders (at least for a few hours) after announcing its first case study for DCVax-Direct as a treatment for inoperable solid tumors.

See More NWBO News...

Sector

Healthcare

Industry

Biotechnology

Northwest Biotherapeutics (NWBO) Description

Northwest Biotherapeutics Website: http://www.nwbio.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks